Drugs / 11C-Glutamine
11C-Glutamine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05322135 | Sep 2022 → Mar 2025 | head and neck squamous cell carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03275974 | Apr 2021 → Dec 2025 | colorectal cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-glutamine | “Patients receive 11C-glutamine intravenously (IV) and undergo PET imaging over 120 minutes.” NCT03275974 ↗ |
| Known as | 11C-Gln | “To establish and validate a 11C-glutamine (11C-Gln) and fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) PET image guided gene signature to predict response to...” NCT03275974 ↗ |
| Known as | Carbon C 11 Glutamine | “Biological: Carbon C 11 Glutamine” NCT03275974 ↗ |
| Modality | Diagnostic / imaging agent | “11C-glutamine PET” NCT03275974 ↗ |
| Route | Intravenous | “Given by IV” NCT03275974 ↗ |